ReviewMediators of inflammation2012
PGI2 as a regulator of inflammatory diseases.
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02370095 (Treprostinil Sodium Inhalation for Patients At High Risk for ARDS), which is not on this map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treprostinil Sodium Inhalation for Patients At High Risk for ARDS: Effect on Oxygenation and Disease-related Biomarkers
Who cites it
94 citing papers in PubMed, 172 citations in OpenAlex.
- Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.European journal of drug metabolism and pharmacokinetics · 2018Trial
- Trial
- Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: A randomized crossover study.Respiratory medicineTrial
- Treprostinil reduces blood pressure and aortic inflammation in hypertension.Clinical science (London, England : 1979) · 2026Article
- The Role of Prostaglandins as Major Inflammatory Mediators in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Prostaglandin IThe Journal of allergy and clinical immunology · 2025Article
- Protective effects of treprostinil and ischemic preconditioning on hepatic ischemia-reperfusion injury and biomarkers in experimental studies in rats.World journal of gastrointestinal surgery · 2025Article
- Calcium Signaling Dynamics in Vascular Cells and Their Dysregulation in Vascular Disease.Biomolecules · 2025Review
- Identifying causal genes for prostatitis through drug-targeted Mendelian randomization.Scientific reports · 2025Article
- Exercise-induced metabolomics and its association with metabolic health in adolescents.Nutrition & metabolism · 2025Article
- Can Bisphenols Alter the Inflammation Process?Life (Basel, Switzerland) · 2025Review
- Ketoprofen Lysine Salt Versus Corticosteroids in Early Outpatient Management of Mild and Moderate COVID-19: A Retrospective Study.Pharmacy (Basel, Switzerland) · 2025Article
- Reactivity of Anomalous Aziridines for Versatile Access to High FspAccounts of chemical research · 2025Article
- Comprehensive Analysis of Metabolic Changes in Mice Exposed to Corilagin Based on GC-MS Analysis.Drug design, development and therapy · 2025Article
- Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis.Current medicinal chemistry · 2025Review
- Omega-3 polyunsaturated fatty acids and pulmonary arterial hypertension: Insights and perspectives.European journal of clinical investigation · 2024Review
- Plasma CXCL4-DNA/RNA Complexes and Anti-CXCL4 Antibodies Modulation in an SSc Cohort under Iloprost Treatment.Reports (MDPI) · 2024Article
- Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog.Arthritis research & therapy · 2024Article
- Article
- Transcriptional responses of brain endothelium toMicrobiology spectrum · 2024Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Prostacyclin, or PGI(2), is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase and PGI synthase (PGIS). The receptor for PGI(2), IP, can be found on a variety of cell types and signaling through this receptor exhibits broad physiological effects. Historically, PGI(2) has been understood to play a role in cardiovascular health, specifically having powerful vasodilatory effects via relaxation of smooth muscle and inhibiting of platelet aggregation. For these reasons, PGI(2) has a long history of use for the treatment of pulmonary arterial hypertension (PAH). Only recently, its importance as an immunomodulatory agent has been investigated. PGI(2) regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature, which may have implications for its further clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.